 | Up a level |
Schuler, A; Huser, J; Schmid, S; Schär, S; Scherz, A; Gautschi, O; Mauti, L; von Briel, T; Waibel, C; Wannesson, L; Pankovics, J; Mark, M T; Rothschild, S I; Addeo, A; Janthur, W D; Siano, M; Boos, L; Britschgi, C; Früh, M (2024). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung cancer, 187(107427), p. 107427. Elsevier 10.1016/j.lungcan.2023.107427
König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494
König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO open, 7(2), p. 100455. Elsevier 10.1016/j.esmoop.2022.100455
